NCT06578975View on ClinicalTrials.gov

HT-ENDO: A Multiomics-based Biomarker for the Diagnosis of Endocrine Hypertension: a Pragmatic, Diagnostic, Randomized, Outcome-based Trial

NANot yet recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Hypertension

Interventions

DIAGNOSTIC_TEST

HT-ENDO-MOS-A13

Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.

OTHER

Normal diagnosis

Standard diagnosis for endocrine hypertension

All Listed Sponsors

lead

JDeinum

OTHER

NCT06578975 - HT-ENDO: A Multiomics-based Biomarker for the Diagnosis of Endocrine Hypertension: a Pragmatic, Diagnostic, Randomized, Outcome-based Trial | Biotech Hunter | Biotech Hunter